Composition for enhancing mitochondrial function
Methods and compositions for reducing symptoms of mental concentration dysfunction, mood dysfunction, and/or stress-related dysfunction. In various examples, the methods include selecting a subject experiencing a symptom of mental concentration dysfunction, mood dysfunction, and/or stress-related dysfunction and providing for consumption by the subject, a nicotinamide composition formulated to reduce a frequency and/or severity of the symptom. The nicotinamide composition includes a first component and a second component. In some examples, the first component includes nicotinamide (NAM), nicotinamide riboside, or nicotinamide mononucleotide and the second component includes one or more salts that provide a choline cation and a succinate anion (2−). In certain examples, the molar ratio of the choline cation:succinate anion (2−):first component is between 2:1:0.01 and 2:1:1.
1. A method for treating a subject experiencing loss of mental focus, the method comprising:
providing for consumption by the subject, a nicotinamide composition formulated to reduce one or more of a frequency and a severity of a loss of mental focus in the subject by synergistically increasing in the subject a level of adenosine triphosphate (ATP), phosphocreatine (PCr), and/or nicotinamide adenine dinucleotide (NADH), the nicotinamide composition comprising:
a first component comprising one of nicotinamide (NAM), nicotinamide riboside, and nicotinamide mononucleotide; and
a second component comprising at least one salt that provides a choline cation and a succinate anion (2−), wherein a molar ratio of the choline cation:succinate anion (2−):first component is between 2:1:0.01 and 2:1:1.
2. A method for treating a subject experiencing one or more of mood swings, bad moods, and seasonal affective disorder, the method comprising:
providing for consumption by the subject, a nicotinamide composition formulated to reduce in the subject one or more of a frequency and a severity of mood swings, bad moods, and seasonal affective disorder, by synergistically increasing in the subject a level of adenosine triphosphate (ATP), phosphocreatine (PCr), and/or nicotinamide adenine dinucleotide (NADH), the nicotinamide composition comprising:
a first component comprising one of nicotinamide (NAM), nicotinamide riboside, and nicotinamide mononucleotide; and
a second component comprising at least one salt that provides a choline cation and a succinate anion (2−), wherein a molar ratio of the choline cation:succinate anion (2−): first component is between 2:1:0.01 and 2:1:1.
3. A method for treating a subject experiencing insomnia and/or mental stress, the method comprising:
providing for consumption by the subject, a nicotinamide composition formulated to reduce one or more of frequency and a severity of insomnia and/or mental stress, by synergistically increasing in the subject a level of adenosine triphosphate (ATP), phosphocreatine (PCr), and/or nicotinamide adenine dinucleotide (NADH), the nicotinamide composition comprising:
a first component comprising one of nicotinamide (NAM), nicotinamide riboside, and nicotinamide mononucleotide; and
a second component comprising at least one salt that provides a choline cation and a succinate anion (2−), wherein a molar ratio of the choline cation:succinate anion (2−):first component is between 2:1:0.01 and 2:1:1.
4. The method of claim 1 , wherein the nicotinamide composition comprises between 10 mg and 4000 mg of the first component.
5. The method of claim 1 , wherein the second component comprises at least one of choline bitartrate and succinic acid disodium salt.
6. The method of claim 1 , wherein the nicotinamide composition further comprises one of creatine and a creatine precursor selected from glycine and arginine.
7. A method for treating a subject experiencing at least one symptom of mood dysfunction, the method comprising:
providing for consumption by the subject, a nicotinamide composition formulated to reduce in the subject one or more of a frequency and a severity of mood swings, bad moods, and seasonal affective disorder, by synergistically increasing in the subject a level of adenosine triphosphate (ATP), phosphocreatine (PCr), and/or nicotinamide adenine dinucleotide (NADH), the nicotinamide composition comprising:
a first component comprising one of nicotinamide (NAM), nicotinamide riboside, and nicotinamide mononucleotide; and
a second component comprising at least one salt that provides a choline cation and a succinate anion (2−), wherein a molar ratio of the choline cation:succinate anion (2−):first component is between 2:1:0.01 and 2:1:1.
8. The method of claim 7 , wherein the second component comprises dicholine succinate (DiSU).
9. The method of claim 8 , wherein an effective amount of the nicotinamide composition comprises between 10 mg and 1000 mg of DiSU.
10. The method of claim 7 , wherein an effective amount of the nicotinamide composition comprises between 10 mg and 4000 mg of the first component.
11. The method of claim 7 , wherein the second component comprises one of choline bitartrate and succinic acid disodium salt.
12. The method of claim 7 , wherein the nicotinamide composition further comprises one of creatine and a creatine precursor selected from glycine and arginine.
13. A method for treating a subject experiencing mental stress dysfunction, the method comprising:
providing for consumption by the subject, a nicotinamide composition formulated to reduce one or more of a frequency and a severity of insomnia and mental stress, by synergistically increasing in the subject a level of adenosine triphosphate (ATP), phosphocreatine (PCr), and/or nicotinamide adenine dinucleotide (NADH), the nicotinamide composition comprising:
a first component comprising one of nicotinamide (NAM), nicotinamide riboside, and nicotinamide mononucleotide; and
a second component comprising at least one salt that provides a choline cation and a succinate anion (2−), wherein a molar ratio of the choline cation:succinate anion (2−):first component is between 2:1:0.01 and 2:1:1.
14. The method of claim 13 , wherein the second component comprises dicholine succinate (DiSU).
15. The method of claim 14 , wherein the nicotinamide composition comprises between 10 mg and 1000 mg of DiSU.
16. The method of claim 13 , wherein the nicotinamide composition comprises between 10 mg and 4000 mg of the first component.
17. The method of claim 13 , wherein the nicotinamide composition further comprises one of creatine and a creatine precursor selected from glycine and arginine.